Verily Partners with Dutch Institutions to Launch Large-Scale Parkinson's Disease Study
Key Insights
Google's life sciences division Verily (search) collaborates with Radboud University Medical Center and ParkinsonNet (search) to study disease progression in 650 Parkinson's patients using advanced imaging and wearable technology.
The study aims to understand individual variations in Parkinson's disease (search) progression and treatment response, potentially enabling more personalized treatment approaches for the 10 million affected globally.
Researchers will utilize real-time data collection through advanced brain imaging, molecular analysis, and wearable devices, with findings to be made freely available to Dutch hospitals and international researchers.
Google's life sciences company Verily (search) has launched a groundbreaking collaboration with leading Dutch institutions to conduct an observational study tracking Parkinson's disease (search) progression, marking a significant step forward in personalized treatment research.
The partnership brings together Verily (search), Radboud University Medical Center, Radboud University in Nijmegen, and ParkinsonNet (search) to monitor 650 patients using cutting-edge technology and data collection methods. This initiative comes at a crucial time, as Parkinson's disease (search) affects over 10 million people worldwide, with numbers expected to rise amid an aging global population.
Advanced Technology Integration
The study will implement a comprehensive data collection approach, combining advanced brain imaging and molecular analysis techniques with wearable devices to monitor patients' activity and vital signs in real-time. While specific details about Verily (search)'s technological contribution remain undisclosed, the company has been reportedly developing a health-focused smartwatch designed to track heart rate and activity levels.
Understanding Individual Disease Patterns
"The disease symptoms, disease progression, and treatment response in Parkinson's disease (search) vary considerably among patients," explains Professor Bastiaan Bloem, founder of ParkinsonNet (search). "Currently, we don't understand what causes these differences and therefore we cannot offer patients a treatment plan that is tailored to their individual needs."
This variability in disease manifestation presents a significant challenge in Parkinson's treatment, making the study's focus on individual disease patterns particularly valuable for advancing personalized medicine approaches.
Data Sharing and Research Impact
Dr. Jessica Mega, Chief Medical Officer at Verily (search), emphasized the company's commitment to neurological research: "We are excited to bring Verily's unique tools and technology to this collaboration in order to more deeply understand Parkinson's disease (search) and discover new insights. This partnership is illustrative of our commitment to Parkinson's disease and other neurological disorders."
In a move to accelerate research progress, all data collected during the study will be made freely available to participating Dutch hospitals for independent research initiatives. International researchers can also access the data by submitting research proposals, fostering global collaboration in Parkinson's research.
Strategic Healthcare Partnerships
This initiative adds to Verily (search)'s growing portfolio of strategic healthcare partnerships, following recent collaborations with major pharmaceutical companies. The company has established Onduo, a joint diabetes management venture with Sanofi, and partnered with GlaxoSmithKline to create Galvani Bioelectronics, focusing on bioelectronic medicines.
The study, which will monitor 44,000 patients in the Netherlands alone, represents a significant step toward understanding and treating Parkinson's disease (search) more effectively through personalized medicine approaches and advanced technology integration.